HAVCR2 and cancer: Targeting Tim-3 along with other checkpoint inhibitors or combining Tim-3 inhibition with new immunotherapeutic approaches that activate cancer-specific T cell stimulatory molecules have immense potential for developing modalities with durable clinical benefits.